Exscientia has advanced a drug candidate for Alzheimer's disease into human testing, the third clinical-stage project for the UK specialist in artificial intelligence (AI) based drug discovery.

However, the rating is weakened by the parent firm's five-year risk-adjusted success ... of equity risk relative to peers. The glide path starts with an allocation of 89% equity, 3 percentage ...

Nonbank lenders continue to increase their grip on the mortgage landscape, taking prime spots among the U.S.'s top 10 mortgage originators. Of the largest mortgage lenders, just four were ...